Difference between revisions of "Fitusiran (ALN-AT3SC)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== siRNA therapeutic, targets antithrombin ==Preliminary data== ===Inherited coagulopathy=== #'''ATLAS-A/B:''' Srivastava A, Rangarajan S, Kavakli K,...") |
m |
||
Line 8: | Line 8: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Subcutaneous medications]] | [[Category:Subcutaneous medications]] | ||
+ | [[Category:Inherited coagulopathy medications (investigational)]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
[[Category:Stub]] | [[Category:Stub]] |
Latest revision as of 21:53, 28 October 2023
Mechanism of action
siRNA therapeutic, targets antithrombin
Preliminary data
Inherited coagulopathy
- ATLAS-A/B: Srivastava A, Rangarajan S, Kavakli K, Klamroth R, Kenet G, Khoo L, You CW, Xu W, Malan N, Frenzel L, Bagot CN, Stasyshyn O, Chang CY, Poloskey S, Qiu Z, Andersson S, Mei B, Pipe SW. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2023 May;10(5):e322-e332. Epub 2023 Mar 29. link to original article PubMed NCT03417245